Annovis Bio Announces Completion of Phase III Parkinson’s Disease Treatment Enrollment at Record Pace

BERWYN, Pa., June 8, 2023 /PRNewswire/ — Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company addressing neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s disease (PD) and developing novel and transformative therapies, announced that its PD phase III study of its lead compound buntanetap has reached full enrollment in a record nine months … Read more